{"id":1537,"date":"2021-03-19T13:46:37","date_gmt":"2021-03-19T13:46:37","guid":{"rendered":"https:\/\/digitone.news\/?p=1537"},"modified":"2021-03-19T13:46:37","modified_gmt":"2021-03-19T13:46:37","slug":"oramed-forms-a-joint-venture-oravax-medical-inc-for-the-development-of-novel-oral-covid-19-vaccines","status":"publish","type":"post","link":"https:\/\/digitone.news\/index.php\/2021\/03\/19\/oramed-forms-a-joint-venture-oravax-medical-inc-for-the-development-of-novel-oral-covid-19-vaccines\/","title":{"rendered":"Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines"},"content":{"rendered":"\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"864\" height=\"752\" src=\"https:\/\/digitone.news\/wp-content\/uploads\/2021\/03\/Nadav.jpg\" alt=\"Kidron\" class=\"wp-image-1538\" srcset=\"https:\/\/digitone.news\/wp-content\/uploads\/2021\/03\/Nadav.jpg 864w, https:\/\/digitone.news\/wp-content\/uploads\/2021\/03\/Nadav-300x261.jpg 300w, https:\/\/digitone.news\/wp-content\/uploads\/2021\/03\/Nadav-768x668.jpg 768w, https:\/\/digitone.news\/wp-content\/uploads\/2021\/03\/Nadav-696x606.jpg 696w, https:\/\/digitone.news\/wp-content\/uploads\/2021\/03\/Nadav-483x420.jpg 483w\" sizes=\"auto, (max-width: 864px) 100vw, 864px\" \/><figcaption>CEO Nadav Kidron<\/figcaption><\/figure>\n\n\n\n<p>Oramed Pharmaceuticals Inc.(<a rel=\"noreferrer noopener\" href=\"http:\/\/www.oramed.com\/\" target=\"_blank\">www.oramed.com<\/a>), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements to form a joint venture focused on the development of novel oral COVID-19 vaccines.\u00a0 The new company, Oravax Medical Inc., is based on Oramed\u2019s\u00a0proprietary POD<sup>TM<\/sup>\u00a0oral delivery technology and\u00a0Premas Biotech Pvt. Ltd.\u2019s\u00a0novel vaccine\u00a0technology.<\/p>\n\n\n\n<p>Oravax\u2019s COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus.&nbsp; The oral delivery of the vaccine should allow for widescale inoculation and easier distribution of the vaccine without requiring an injection.<\/p>\n\n\n\n<p>In a pilot animal study, the oral COVID-19 vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA).&nbsp;<\/p>\n\n\n\n<p>Oravax anticipates commencing a clinical study during the second quarter of 2021.<\/p>\n\n\n\n<p>\u201cAn oral COVID-19 vaccine would eliminate several barriers to rapid, widescale distribution, potentially enabling people to take the vaccine themselves at home. While ease of administration is critical today to accelerate inoculation rates, an oral vaccine could become even more valuable in the case that a COVID-19 vaccine may be recommended annually like the standard flu shot,\u201d said Nadav Kidron, CEO of Oramed.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oramed Pharmaceuticals Inc.(www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements to form a joint venture focused on the development of novel oral COVID-19 vaccines.\u00a0 The new company, Oravax Medical Inc., is based on Oramed\u2019s\u00a0proprietary PODTM\u00a0oral delivery technology and\u00a0Premas Biotech Pvt. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1538,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[],"class_list":{"0":"post-1537","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-biotech"},"_links":{"self":[{"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/posts\/1537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/comments?post=1537"}],"version-history":[{"count":1,"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/posts\/1537\/revisions"}],"predecessor-version":[{"id":1539,"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/posts\/1537\/revisions\/1539"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/media\/1538"}],"wp:attachment":[{"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/media?parent=1537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/categories?post=1537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/digitone.news\/index.php\/wp-json\/wp\/v2\/tags?post=1537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}